NCT05277766View on ClinicalTrials.gov

Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

November 21, 2022

Primary Completion Date

January 31, 2026

Study Completion Date

April 30, 2027

Conditions
Peritoneal CarcinomatosisPeritoneal MetastasesColorectal CancerSmall Bowel CancerAppendix CancerGastric CancerPancreatic CancerBile Duct Cancer
Interventions
DRUG

PIPAC with Nal-IRI

Nanoliposomal irinotecan (Nal-IRI, Onivyde) will be administered intraperitoneally using the PIPAC technique. The administered dose will escalate ranging from 30 to 90 mg/m². PIPAC will be performed every 4 to 6 weeks for 3 cycles.

Trial Locations (1)

9000

RECRUITING

UZ Ghent, Ghent

All Listed Sponsors
collaborator

Kom Op Tegen Kanker

OTHER

collaborator

University Ghent

OTHER

lead

University Hospital, Ghent

OTHER